Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches

Table 1 Clinical study outcomes of ipilimumab (anti-cytotoxic T lymphocyte associated antigen-4) in solid tumors

Ref.	Phase	Cancer type	No. of patients	Dose (mg/kg)	Outcome
McDermott et al[73]	3	Melanoma	676	3	3-yr survival rate 25%
Hodi et al[74]	3	Melanoma	676	3	BORR: 10.9%
Robert et al[70]	3	Melanoma	676	3	BORR: 37.5%
Margolin et al[71]	2	Melanoma with brain metastasis	93	10	1Cohort A: 18% disease control 2Cohort B: 5% disease control
Di Giacomo et al[69]	N/A	Melanoma	27	10	2-yr survival rate 23.5%
Yang et al[78]	2	Pancreatic adenocarcinoma	27	3	No responders
O’Day et al[68]	2	Melanoma	155	10	BORR: 5.8%
Wolchok et al[67]	2	Melanoma	217	10	BORR: 11.1%
Yang et al[78]	2	RCC	40	3	PR: 12.5%
Phan et al[66]	1	Melanoma	14	3	OR: 21%

¹Cohort A includes neurologically asymptomatic patients not receiving corticosteroids;

²Cohort B includes symptomatic patients receiving corticosteroids. Dose indicates dose of Ipilimumab. Outcomes are best outcomes in each study, in patients receiving Ipilimumab only. BORR: Best overall response rate; RCC: Renal cell carcinoma; PR: Partial response; OR: Objective response; N/A: Not available.